Pulmonary Medicine and Tuberculosis, The Third People's Hospital of Shenzhen, The National Clinical Research Center for Infectious Diseases, Shenzhen, China.
Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Drug Discov Ther. 2022 May 17;16(2):96-98. doi: 10.5582/ddt.2022.01024. Epub 2022 Apr 20.
Linezolid has been one of the key anti-tuberculosis agents for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB). It used to be very expensive and was not covered by social insurance from local governments. Nevertheless, a growing number of patients in China received linezolid in their anti- MDR/XDR TB regimens over the past decade. Many scholars in China have reported their experience using linezolid to treat patients with MDR/XDR-TB. In view of this, existing evidence of the efficacy and safety of linezolid and problems faced by Chinese patients with MDR/XDR-TB are summarized here.
利奈唑胺一直是治疗耐多药结核病（MDR-TB）/广泛耐药结核病（XDR-TB）的关键抗结核药物之一。它曾经非常昂贵，并且未被地方政府的社会保险覆盖。然而，在过去十年中，中国越来越多的 MDR/XDR-TB 患者接受了利奈唑胺治疗。中国的许多学者已经报告了他们使用利奈唑胺治疗 MDR/XDR-TB 患者的经验。鉴于此，本文总结了利奈唑胺的疗效和安全性的现有证据，以及中国 MDR/XDR-TB 患者面临的问题。
